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The exact magnitude of the benefit of influenza vaccine among 
elderly individuals is subject of considerable debated. Existing 
vaccine effectiveness estimates come mostly from observational 
studies, which may be biased because of difficulties in identify-
ing and adjusting for confounders. In this paper, we examine the 
potential sources of bias in observational studies of influenza 
vaccine effectiveness in the elderly and we discuss available 
evidence regarding the efficacy and effectiveness of licensed 
influenza vaccines. Although several methodological criticisms 
among the available analyses on seasonal vaccines for elderly 
were identified, overall seasonal influenza vaccines showed rel-
evant efficacy/effectiveness in reducing the risk of influenza and 
its complications in the elderly, considering different measure 
of outcome.
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Summary
Introduction
Influenza infection is associated with considerable year-
ly morbidity and subjects aged ≥ 65 years are among 
those at highest risk of serious outcomes [1, 2].  Annual 
influenza vaccination, that is considered the most effec-
tive strategy to prevent influenza by the World Health 
Organization, is recommended for elderly in many de-
veloped countries [3]. However, the exact magnitude of 
the benefit of the current immunization strategy among 
older adults is a subject of considerable debate [4-10]. 
Most estimates of the influenza vaccine effectiveness 
(IVE) are based on studies using different designs and 
outcomes, which provided a wide range of IVE esti-
mates in the elderly (adults ≥ 65 years-old) [10, 11]. Fur-
thermore, as most of the IVE studies are observational, 
they are susceptible to bias. Confounding factors such as 
comorbidities or functional status can alter the estimates 
and different methods to adjust for these confounding 
factors have been suggested [5, 12]. The present study 
discusses available epidemiological studies estimating 
IVE and criticisms in the evaluation of influenza vaccine 
efficacy and effectiveness, defined as the relative reduc-
tion in influenza risk after vaccination as established by 
a randomized placebo-controlled clinical trial (RCT) 
and the relative reduction in influenza risk in vaccinated 
individuals in observational studies that used medically 
attended, laboratory-confirmed influenza as the primary 
outcome of interest, respectively [13].
Criticisms in the evaluation of influenza 
vaccine efficacy and effectiveness
Which epidemiological study can estimate 
influenza vaccine effectiveness?
Not many RCTs on the influenza vaccine efficacy in older 
adults have been conducted, because of ethical issues con-
cerning interventions that are recommended  [14]. In the 
last two decades, the only large RCT of inactivated influen-
za vaccine in adults aged ≥ 60 years was conducted during 
a single season and it was limited to healthy subjects. This 
RCT demonstrated a reduction in risk of serologically con-
firmed uncomplicated influenza infection in participants 
60-69 years-old, with an estimated efficacy for prevention 
of serologically-confirmed influenza in symptomatic sub-
jects of 58%, but no strong conclusions about the IVE could 
be drawn about those ≥ 70 years-old because this RCT was 
inadequately powered to examine the efficacy of the vac-
cine in this age group [15]. Moreover, the efficacy evidence 
in healthy subjects 60-69 years-old may not apply to fragile 
elderly ≥ 70 years-old because advanced age and the co-
morbidities are associated with an increased risk of compli-
cations and the weakening of the immune system [16-22]. 
Without satisfactory data from RCTs, estimates of IVE 
among older subjects result from observational studies, 
typically from retrospective cohort studies, which may be 
biased [12, 23]. Many observational studies have compared 
the risk of hospitalization pneumonia-related and all-cause 
mortality in vaccinated and unvaccinated elderly during 
influenza season and have reported significant reductions 
in risk for vaccinated subjects, with reductions of 50% for 
all-cause mortality and of 27-33% for pneumonia and in-
fluenza hospitalization  [24-41]. Some authors interpreted 
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these results as evidence that influenza vaccine substan-
tially reduces the risk of death and hospitalization in the el-
derly [11, 42-46]. Nevertheless some studies, as the review 
published in 2007 by Simonsen et al. [9], state that there is 
evidence for bias in estimated risk reductions for vaccinat-
ed versus unvaccinated elderly in available observational 
studies, especially those not using laboratory-confirmation 
as outcome, that is considered the gold standard. Simonsen 
et al. [9] observed that the finding of reductions ≥ 50% in 
all-cause mortality for vaccinated elderly during influenza 
season is implausible, considering that influenza accounts 
for a maximum of 10% of all deaths during influenza sea-
son  [47] and, therefore, influenza vaccine could at most 
prevent 10% of deaths, even if the vaccine efficacy was 
100% in the elderly. Furthermore, estimated risk reduc-
tions for vaccinated elderly are not specific to seasons 
with a matching between the circulating and vaccine in-
fluenza strains. Nordin et al. reported large reductions in 
risk of death and hospitalization in vaccinated elderly in 
the 1997-1998 influenza   [33], characterized by a mis-
match and during which a RCT found no vaccine effect 
in healthy adult workers [48]. Moreover, the greatest ap-
parent vaccine benefit has been observed before influenza 
season, when no effect is expected [5]. Two further stud-
ies [5,  47] are of particular interest. In 2005 Simonsen et 
al. conducted an ecologic study [47] and reported that, de-
spite substantial increases in vaccine coverage (VC) from 
about 15% in 1980 to ≥ 65% by 2001 in elderly, rates of 
winter excess morbidity and mortality have not declined 
during this period. If the estimated mortality reduction of 
50% by influenza vaccine is real, the observed excess mor-
tality rate should have decreased with increasing VC [12]. 
Second, a large cohort study [5] assessed the risk of death 
and hospitalization in vaccinated and unvaccinated elderly 
in both influenza and non-influenza periods. The study 
confirmed that vaccinated subjects 60-69 years-old were 
at lower risk (44% for all-cause death) during influenza 
season, but revealed a larger risk reduction before the on-
set of influenza season (61% for all-cause death), when the 
IVE is expected to be 0%. Therefore this finding suggests 
the presence of confounding and any estimated difference 
in risk between vaccinated and unvaccinated elderly dur-
ing this period is related to bias. Similar bias were found 
in pre-influenza estimates of the association between vac-
cination and other outcomes, including hospitalizations for 
pneumonia or influenza. Finally, available observational 
studies about IVE frequently use data from databases, such 
as the General Practitioners Research database, health care 
utilization data systems, or those kept by some health 
maintenance organizations in the United States  [12]. In 
2005 Schneeweiss and Avorn published a review about 
general methodological issues that arise using these data-
bases in health research, such as data inaccuracies and re-
sidual confounding, but they didn’t discuss methodologi-
cal criticism specific to influenza vaccination [49]. 
The “case-coverage” or “case-cohort” method is another 
type of study to estimate IVE. In this case, vaccination 
rates among cases are compared with those in a simi-
lar cohort (which may include individuals who develop 
cases) over a defined period of time [50]. This method 
has been used in a study published in 2008 by Szilagyi 
et al. that evaluated IVE among children 6-59 months of 
age during 2 influenza seasons  [51]. The authors con-
cluded that this type of study design is “inefficient and 
may insufficiently account for important factors, such as 
propensity to seek care” and that it has “important limi-
tations in being able to annually assess IVE”. 
In recent years, the test-negative design, that is an analo-
gous to the indirect cohort study [50], has arisen as the 
preferred method for estimating IVE in observational 
studies [52]. This type of study design consider as study 
subjects all persons who seek care for an acute respira-
tory illness (ARI) and who are tested for influenza infec-
tion. IVE is estimated from the ratio of the odds of vac-
cination among subjects testing positive for influenza to 
the odds of vaccination among subjects testing negative. 
The main advantage of this study design is that it allows 
removing differences in health care-seeking behavior 
between vaccinated and unvaccinated subjects in the 
study design phase. 
Which factor may interfere with vaccine 
effectiveness estimates?
Vaccine effectiveness can be measured using different 
endpoints, each of which has advantages and disadvan-
tages [53]. In the recent past, the most frequently consid-
ered endpoints include the incidence of clinically defined 
influenza-like illness (ILI) and laboratory-confirmed in-
fluenza. The methods used to the laboratory confirmation 
include viral culture, serologic rises between pre and post 
influenza season samples and molecular methods  [53]. 
Unfortunately, none of these are both specific and sensi-
tive methods. Typically influenza presents with the acute 
onset of fever, myalgia and cough [54]. The Centers for 
Disease Control and Prevention (CDC) defined ILI as 
fever with either cough or sore throat for research pur-
poses [55]. This CDC-ILI definition has high positive pre-
dictive value in young adults (86.8%) [56] during periods 
of high influenza activity, but it is much lower in older 
adults, who frequently don’t have fever and other mani-
festations of influenza [57, 58]. Furthermore, vaccine im-
pact on severe outcomes such as hospitalization and death 
may be difficult to measure because of the large sam-
ple sizes needed to accurately estimate rare events like 
these  [59]. Conventionally, culture has been considered 
the gold-standard for the diagnosis of influenza [53]. Nev-
ertheless, viral titers in the respiratory secretions of older 
adults are generally lower than those of younger adults 
and children, reducing the sensitivity of culture in this 
age group when compared with serology and polymerase 
chain reaction (PCR) [60].  Serology is another common 
but not sensitive endpoint for estimating IVE. A positive 
case of influenza is usually defined as a ≥ 4-fold rise in 
antibody titers between the pre- and post-season serol-
ogy [53]. Some authors have suggested that this endpoint 
might overestimate the efficacy of vaccine because of the 
“antibody ceiling” phenomena, that could be explained as 
follows: once antibody titres have increased in response 
to the vaccine, they could go no higher in response to 
infection  [61]. Furthermore, the association of immune 
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correlates of vaccine protection with efficacy against dis-
ease is not always dependable endpoint [62], particularly 
weak in young children, the elderly and immunocompro-
mised, i.e. target groups that may respond least well to 
vaccination [63].  Use of real-time PCR (RT-PCR) with 
appropriately designed primers and probes for detecting 
influenza infection has now become the gold standard ant 
it should be the primary end point used in future efficacy 
studies [64]. The test is highly sensitive, so much so that 
concerns has been raised that it might detect subclinical 
infections that are not clinically relevant [64]. Isolation 
in cell culture must still be used in those RT-PCR posi-
tive to further characterize the viruses, but use it alone as 
an endpoint could result in missed cases and biased re-
sults [64, 65].
Potential bias in estimates of influenza 
vaccine effectiveness
The risk of selection bias in observational studies esti-
mating IVE has been discussed in many available stud-
ies  [4-6, 8, 9, 12].
Although universally recommended for old subjects, ac-
ceptance of influenza vaccine is voluntary and a prefer-
ential receipt of vaccine by motivated relatively healthy 
elderly and a selective underuse by frail elderly were 
demonstrated  [5-7, 9, 12]. Healthy adherer bias may be 
more noticeable for influenza vaccine than other type of 
exposures for several reasons. First, limited availability 
of vaccine (late autumn and winter) may limit the chance 
for vaccination. Several studies demonstrated that elderly 
subjects who have a car or can walk to their health care 
provider’s office  [66], live with others who can assist 
them  [67], or have fewer functional limitations  [6] are 
more prone to be immunized. A case-control study of all-
cause mortality conducted in 824 elderly during influenza 
season found that severe functional limitation, in particu-
lar requiring assistance for bathing, was associated with a 
13-fold increased risk of death and a 52% decreased like-
lihood of vaccination [6]. Therefore, disability appears as 
a contributing factor in the decision to receive or resist 
vaccination near the end of life. A further factor that may 
aggravate bias is the use of all-cause death as a study out-
come, because it is nonspecific and so expected vaccine 
effects are small and thus difficult to distinguish from 
confounding, which may be large  [68]. To differentiate 
vaccine effects from bias, Fireman et al. has proposed a 
“difference in differences” approaches [4]: if the flu vac-
cine really does prevent deaths, then in a large population 
there should be a detectable difference between: (i)  the 
difference in the odds of prior vaccination decedents and 
survivors that is observed on days when influenza is cir-
culating and (ii) the difference in the odds of prior vac-
cination between decedents and survivors that would be 
expected on the same calendar dates if influenza were not 
circulating. The implementation of the “difference in dif-
ferences” approach consisted of tracing the trajectory of 
the bias over time and comparing the vaccination-mor-
tality association inside flu season with that outside flu 
season. Estimated VE against all-cause mortality during 
1996-2005 flu seasons was 4.6% (95% CI: 0.7 – 8.3). Al-
though this estimate may seem unsatisfactory, it amounts 
t approximately 47% of a plausible target: the rise in 
mortality that would have occurred during flu season had 
none of the elderly been vaccinated.
Available estimates of influenza vaccine 
efficacy and effectiveness against  
lab-confirmed influenza in adults aged 50 
years and older obtained  
by meta-analyses
A considerable body of evidence has been produced on 
influenza vaccines for different types of virus strains and 
various populations and settings [69]. Between 1995 and 
2011 numerous meta-analyses evaluating the benefits 
and harms of influenza vaccines mainly in adults and 
elderly have been published, as an effort to integrate this 
evidence [13, 44, 70-77]. In 2012 Osterholm et al. [13] 
published a meta-analysis of RCTs and observational 
studies that assesses the highest quality evidence about 
the efficacy and effectiveness of licensed influenza vac-
cines in the USA using RT-PCR or viral culture to con-
firm influenza infections. Vaccine efficacy was defined 
as “the relative reduction in influenza risk after vacci-
nation as established by a RCT”. Vaccine effectiveness 
was defined as “the relative reduction in influenza risk 
in vaccinated individuals in observational studies (case-
control, case-cohort and prospective cohort studies) that 
used medically attended, laboratory-confirmed influen-
za as the primary outcome of interest” [50]. Laboratory-
confirmed influenza was defined as RT-PCR-confirmed, 
the preferred diagnostic test for influenza because char-
acterized by high sensitivity and low probability of false 
positive [78], or culture-confirmed influenza. Trivalent 
influenza vaccine (TIV) efficacy and effectiveness stud-
ies that considered serology endpoints to diagnose in-
fluenza were excluded because of bias in case detection 
in immunized subjects  [64, 79]. For all the considered 
studies, efficacy and effectiveness were evaluated as sta-
tistically significant if the 95% CI did not cross 0.
Efficacy
None of the evaluated RCTs assessing TIV efficacy ex-
clusively considered subjects aged ≥ 65 years-old and this 
is attributable to ethical issues. For LAIV, the only RCT 
conducted in adults aged ≥ 60 years-old reported signifi-
cant overall efficacy (42%, 95% CI: 21-57), but estimated 
efficacy was lower in subjects aged 60-69 years-old (31%) 
and higher in those aged ≥ 70 years-old (57%)  [80].
Effectiveness
Several observational studies about influenza vaccines 
effectiveness have been conducted  [13], especially on 
TIV. Main recent evidences are following described. 
Since 2007 the European Centre for Disease Prevention 
and Control (ECDC) has promoted I-MOVE (Influenza 
Monitoring Vaccine Effectiveness), a network to moni-
C. TRUCCHI eT al.
E40
tor seasonal and pandemic IVE in the European Union 
(EU) and European Economic Area (EEA) [81]. Initial 
phase of I-MOVE network include five case-control and 
two cohort studies evaluating IVE in 2008-2009 season. 
The studies were piloted in the network of active General 
Practinioners (GP)-based influenza sentinel surveillance 
systems and assessed IVE against laboratory confirmed 
influenza in community-dwelling elderly [82]. The esti-
mated crude IVE in the pooled analysis was 55.1% (95% 
CI: 27.8-72.1%). The overall IVE adjusted for study, age, 
sex, presence of chronic conditions, previous hospitali-
zations, smoking history, functional status, and previous 
influenza vaccination was 59.1% (95% CI: 15.3-80.3%). 
The adjusted IVE in subjects 65-74 year-olds was 65.4% 
(95% CI: 15.6-85.8%) and 59.6% (95%: CI: -72.6-90.6%) 
in the age-group of ≥ 75 years. Spain participated in I-
MOVE project with a case-control study using two dif-
ferent control groups. IVE against laboratory-confirmed 
influenza in elderly ≥ 65 years was also estimated by 
Savalescu et al. using the screening method  [83]. Both 
designs (case-control and screening method) were carried 
out in the frame of the Spanish Influenza Sentinel Surveil-
lance System (SISSS) in 2008-2009 season. Participating 
sentinel GPs of the framework swabbed all patients who 
were attended for ILI. Study cases were defined as “ILI 
patients swabbed and laboratory confirmed for influenza 
by RT-PCR or culture”. The first control group included 
ILI cases testing negative for influenza (test-negative 
controls) and the second one comprised patients not hav-
ing had respiratory symptoms since the beginning of the 
season (non-ILI controls). The crude estimated IVE was 
86% (95% CI: 43-98) and the IVE adjusted for chronic 
conditions, previous hospitalizations, functional status, 
smoking, previous influenza and pneumococcal vaccina-
tion was 79% (95% CI: -26-96). In the same period Talbot 
et al. conducted a prospective observational study, pub-
lished in 2012 [53]. Patients aged ≥ 50 years with respira-
tory symptoms or fever hospitalized in Davidson County, 
TN (Nashville) during three influenza seasons (2006-
2007, 2007-2008 and 2008-2009) were enrolled and in-
fluenza vaccination status was compared in those with 
and without laboratory-confirmed influenza by RT-PCR 
to estimate IVE for the prevention of hospitalization. For 
each of the three evaluated seasons, unadjusted annual es-
timates were 59.4% (95% CI: -26.7-87%), 61.8% (95% 
CI: -29.4%-88.7%) and 81.8% (95% CI: 34.8-94.9%), 
respectively. With propensity-score adjustment, overall 
IVE for the three influenza seasons was 61.2% (95% CI: 
17.5-81.8%). 
Available estimates of TIV efficacy  
and effectiveness against influenza  
in the elderly obtained by umbrella review
Given that published meta-analyses on influenza vaccine 
efficacy and effectiveness evaluated different types of 
vaccines, different age-groups and used different strati-
fied analyses and study selection criteria, it’s difficult to 
obtain a clear picture of vaccine benefits examining sin-
gle meta-analyses [69]. Consequently, in 2012 Manzoli 
et al. conducted an umbrella review, i.e. an over-arching 
evaluation of all recent meta-analyses on vaccine effi-
cacy and effectiveness (Fig. 1). 
Four meta-analyses including both RCTs and observa-
tional studies on TIV conducted in the elderly were dis-
cussed [13, 44, 76, 84].
Two meta-analyses estimated vaccine efficacy/effec-
tiveness against laboratory-confirmed cases of influenza 
(LCC)  [13,  84]. Influenza vaccine efficacy estimated by 
RCTs was 58% (95% CI: 34%-73%), while the estimates of 
IVE from cohort studies varied from 41% (95% CI: -15%-
70%) in the Jefferson et al. meta-analysis, that included 
only LCC based on serology, to 63% (95% CI: 28%-81%) 
in the Osterholm et al. meta-analysis, that evaluated a more 
specific outcome (RT-PCR or culture-confirmed influenza 
infections only). Concerning clinically confirmed cases 
(CCC), all considered reviews demonstrated that influenza 
vaccine confer significant protection. The four evaluated 
RCTs estimated a summary efficacy of 41%, while the me-
ta-analyses of cohort studies showed an overall IVE rang-
ing from 56% [44] to 24% [84]. 
Three meta-analyses evaluated also other out-
comes [44, 76, 84], demonstrating that TIV was signifi-
cantly better than placebo in preventing hospitalizations 
due to influenza or pneumonia. However the estimates 
varied, ranging from 48% [44] to 27% [84]. 
Three meta-analyses considered the outcome mortal-
ity  [44,  76,  84]. Unexpectedly, the estimates of IVE 
in preventing mortality due to influenza or pneumonia 
were similar to those of all-cause mortality [47].
Combining observational studies, all meta-analyses 
demonstrated a significant reduction of deaths for all 
causes, with IVE ranging from 68% to 47%. 
The effect of vaccination is expected to be higher in case 
of a good antigenic matching between the circulating and 
the vaccine strains [85]. However, Gross et al. observed 
a significant IVE even in seasons in which mismatch-
ing was demonstrated [44]. Jefferson et al. [84] observed 
that IVE in preventing hospitalization due to influenza 
or pneumonia and all cause mortality was substantially 
higher in seasons with good matching. Nevertheless, in 
2010 Dean et al. published a cluster randomized trial, 
which demonstrated that influenza vaccine can be effec-
tive against disease and severe outcomes despite incom-
plete vaccine match [86]. 
Manzoli et al. summarized that Gross et al. [44] and Vu 
et al. [76] observed that influenza vaccines are effective 
in preventing influenza cases, hospitalizations and deaths 
in the elderly, while Osterholm et al. stated that “evidence 
for protection in adults aged 65 years or older is lack-
ing”  [13]. However, the conclusions by Osterholm et al. 
could be due to the choice of restrictive inclusion crite-
ria [87]. Jefferson et al. stated that “the available evidence 
is of poor quality and provides no guidance regarding the 
safety, efficacy or effectiveness of influenza vaccines for 
people aged 65 years or older,” but these observation may 
be influenced by the evidence of potential biases [84].
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Conclusions
The overall evidences suggest that most influenza vac-
cines confer relevant protection against naturally acquired 
infection also in the elderly, who are at increased risk 
for influenza and complications due to influenza infec-
tion [53, 69, 88]. However, the assessment of vaccine ben-
efits is still affected by considerable methodological chal-
lenges [88]. There is evidence for the presence of bias in 
available observational studies estimating the IVE in the 
elderly and that current adjustment methods could not ad-
equately control it [12]. Some of the outcomes evaluated in 
the comprehensive umbrella review by Manzoli et al. seem 
to be surprising when compared, i.e. the large impact on 
all-cause mortality in the elderly as opposed to far more 
modest effects against CCC  [69]. However, Manzoli et 
al. concluded that “although several discrepancies among 
meta-analyses on seasonal vaccines for elderly were iden-
tified, most seasonal influenza vaccines show statistically 
significant efficacy/effectiveness, the magnitude of which, 
however, largely varied” [69]. The conduct of adequately 
powered publicly-funded RCTs on elderly could be a solu-
tion, but this would be also an expensive and an ethically 
complex proposal, because the use of influenza vaccines is 
recommended worldwide from several years [69, 88] and 
cost-effectiveness issues have to be properly re-assessed in 
times of economic recession [89]. 
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